

Supporting Information

Alfaro et al. 10.1073/pnas.0803437105

SI Materials and Methods

Materials

Antibodies. Ly-6A/E/ScaI (clone E13-161.7; BD Pharmingen, 553336), CD11b (clone M1/70; BioLegend 101215) or (clone M1/70; R&D Systems, MAB1124), CD14 (clone biG 53; Alexis ALX-804-499-C100) or (clone TuK4; Caltag Laboratories), CD16/32 (clone 93; eBioscience, 14-0161), CD44 (clone KM81; Cedarlane, CL8944F), CD144 (clone 11D4.1; Fitzgerald, RDI-MCD 144-11D4), CD146 (clone P1H12; Chemicon International, MAB16985), Dkk1 (lot GLB01; R&D Systems, AF1096), Sfrp2 (clone 331022; R&D Systems, MAB1169), Wnt3a (clone 217804; R&D Systems, MAB1324), CD31/platelet endothelial cell adhesion molecule-1 (PECAM-1; clone 557355, PharMingen)

Recombinant Proteins. Dkk1 (lot MCB056011; R&D Systems; catalog no. 1765-DK), PDGF-BB (lot BW17; R&D Systems; catalog no. 220-BB), Sfrp2 (R&D Systems; catalog no. 1169-FR), Sfrp3 (R&D Systems; catalog no. 592-FR), Sfrp4 (R&D Systems; catalog no. 1827-SF), Wnt3a (R&D Systems; catalog no. 1324-WN).

cDNA. Sfrp2 (GenBank accession no. BC014722; ATCC; catalog no. 6465272), Wnt3a (GenBank accession no. X56842; ATCC; catalog no. MBA-176), Dkk1 (GenBank accession no. NM012242; E. Lee, Vanderbilt University)

Animals/Surgical Interventions

Repair/Granulation Tissue Stimulation. To compare MSCs from disparate strains without inciting immune mediated rejection, we used the immunodeficient NOD/SCID strain. Some of the NOD/SCID mice also contained an inactivating mutation in the β -gluc gene to enable precise tracking and quantification of exogenous MSCs (1). β -gluc is a lysosomal enzyme that is expressed in all cell types, including human and mouse BM-derived cells. Upon transplantation into a β -gluc-negative host, cells from normal human and/or murine donors (e.g., exogenously added MSCs) can be identified by virtue of their β -gluc expression at a level of single cell sensitivity by quantitative biochemical or histochemical techniques (1–4). Biochemical measure of β -gluc activity correlated with MSC numbers in sponges in a linear manner (data not shown). Each mouse was implanted with multiple sponges (PBS, WT, MRL or various WT-MSC transducts, sFRP2, GFP, or Dkk1-MSCs) to enable evaluation of sponge repair tissues mediated by MSCs/PBS within the same animal and between experimental mice. Animals were taken down between 14 and 21 days after sponge implantation. **Myocardial Infarction:** Since functional outcome or infarct size was not significantly different between WT-MSCs and GFP-MSCs, the data were combined for subsequent comparisons. Postsurgical echocardiograms were obtained on unsedated mice from 2-D guided M-mode images (100 frames/sec) with 3 consecutive cardiac cycles measured to obtain the mean cardiac dimensions. Echocardiograms were read blinded using short axis and a parasternal long-axis views with the leading edge method. To measure infarct size, excised hearts were immersion-fixed in 10% buffered formalin for 24 h and transferred to 70% ethanol after which serial sections through the ventricles were made parallel to the atrioventricular groove. The samples were then processed for light microscopy. Paraffin sections cut at 6 μ m were stained with H & E and Masson trichrome. Infarcted areas on trichrome-stained slides were quantified in all sections as the


percentage of left ventricle that exhibits myocyte replacement by scar using Image Pro software (Media Cybernetics) (5).

Cells. Primary MSC cells were generated from pooled BM from $n = 3$ mice. Two independently isolated primary MSCs were used for both WT and MRL experiments and representative data presented. The immunophenotype of MSCs was assessed for the presence of CD44 and LY6A/E/ScaI by FACS analysis on a LSMII flow cytometer and subsequently analyzed using FACS-Diva v5.02 software (Becton Dickinson). Isotype control antibodies were used to establish quadrants. Nonviable cells, identified by 7-aminoactinomycin D (7-AAD) (Molecular Probes) staining, were excluded. Absence of CD45, CD14, CD11b, CD16/32, CD144, and CD146 expression was confirmed by immunofluorescence microscopy of acetone-fixed coverslips (data not shown) using a Zeiss Axioplan microscope as previously reported (4). MSCs were maintained in DMEM-LG (Biowhittaker), 10% defined FBS (HyClone, Mediatech; Cellgro), antibiotics, fungizone and 20 μ g/ml PDGF. BrdU Cell Proliferation Assay (Calbiochem) was used to quantify the proliferation of the MSCs. Briefly, 0.5×10^3 cells were seeded on 96 well plates and serum starved for 6 h. The cells were grown in full media for the next 12 h before the addition of BrdU for 16 h before analysis. β -gluc enzyme specific activity of sponge homogenates was measured as described in ref. 1 and was normalized to DNA content using the FluoReporter Blue Fluorometric dsDNA Quantitation Kit (Molecular Probes) according to manufacturer's instructions.

RNA Isolation/Microarray. RNA was isolated using TRIZOL reagent (Invitrogen) and purified according to manufacturer's instructions using RNeasy Mini Kit (Qiagen). The Affymetrix One Cycle reaction was initiated using a sample mix of high-quality total RNA, polyA spike in controls (included in kit), 50 μ M T7 dT oligo, and H₂O. First strand synthesis mix (5X first strand buffer, 0.1 M DTT, 10 mM dNTP, SuperScript II) is added to the sample mix and incubated at 42°C for 1 h, with cooling to 4°C for 5 min. Subsequently, second strand synthesis mix (second strand buffer mix, 10 mM dNTP mix, E. Coli DNA ligase, E. Coli DNA polymerase I, E. Coli Rnase H) is added to the sample mix, and incubated at 16°C for 2 h. At this point, T4 DNA polymerase is introduced, and incubated at 16°C for 5 min, followed by the addition of 0.5M EDTA to stop the reaction. The samples are then purified by binding to and elution from a Qiagen column. The resulting cDNA is labeled and amplified in an IVT reaction using biotinylated nucleotides. The reaction is done by adding the purified cDNA to labeling mix (10X IVT labeling buffer, IVT labeling NTP mix, IVT labeling enzyme mix, H₂O) and incubating 16 h at 37°C. The biotinylated cRNA molecules are purified by binding and eluting from a Qiagen column. After quantification, 20 μ g of the reaction products are fragmented using fragmentation buffer and H₂O, and incubated at 94°C for 35 min. Fragmentation reaction products and non-fragmented cRNA samples are compared with bioanalysis to ensure that fragmentation is complete. Fragmented samples were then hybridized to the chip Mouse 430 2.0 array, stained and scanned (Affymetrix GeneChip Scanner 3000 7G with AutoLoader). Analysis of the probe levels was performed using robust multi array average (RMA) normalization. GeneSpring 7.3 (Agilent Technologies) was used for the analysis and visualization of the RMA-transformed data. t test with confidence level of $P < 0.05$ was used. Duplicates of each sample were run.

1. Young PP, Hofling AA, Sands MS (2002) VEGF increases engraftment of bone marrow-derived endothelial progenitor cells (EPCs) into vasculature of newborn murine recipients. *Proc Natl Acad Sci, USA* 99:11951–11956.
2. Soper BW, Duffy TM, Vogler C, Barker JE (1999) A genetically myeloablated MPS VII model detects the expansion and curative properties of as few as 100 enriched murine stem cells. *Exp Hematol* 27:1691–1704.
3. Young PP, Vogler C, Hofling AA, Sands MS (2003) Biodistribution and efficacy of donor lymphocytes in a murine model of lysosomal storage disease. *Mol Ther* 7:52–61.
4. Teleron AA, Carlson B, Young PP (2004) Blood donor white blood cell reduction filters as a source of human peripheral blood-derived endothelial progenitor cells. *Transfusion* 45:21–25.
5. Pfeffer MA, et al. (1979) Myocardial infarct size and ventricular function in rats. *Circ Res* 44:503–512.
6. Ireton RC, et al. (2002) A novel role for p120 catenin in E-cadherin function. *J Cell Biol* 159:465–476.
7. Tropel P, et al. (2004) Isolation and characterisation of mesenchymal stem cells from adult mouse bone marrow. *Exp cell Res* 295:395–406.
8. Farndale RW, Buttle DJ, Barrett AJ (1986) Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. *Biochimica et Biophysica Acta* 883:173–177.

a. Reduced MRL-MSC mediated granulation tissue with LiCl treatment



b. Reduced MRL-MSC engraftment with LiCl treatment




Fig. S2. Effects of Wnt signaling on MSCs. (a) Representative low power Trichrome images show decreased granulation tissue in MRL-MSC-loaded sponges treated with Lithium Chloride (LiCl) vs. PBS control. Note that LiCl (Wnt activation) promoted *in vivo* differentiation of MSCs into cartilage. (b) Graphical representation of β -glucuronidase activity as a marker of MSC engraftment in the presence or absence of LiCl treatment. Two-tailed, unpaired student's *t* test was performed to compare the effects of LiCl on the levels of engraftment. Asterisk designates statistical significance of $P \leq 0.05$. NS, no statistical difference.






Fig. S4. Wnt inhibition of murine MSCs through Dkk1 does not promote MSC proliferation and engraftment. (a) WT-MSCs were retrovirally transduced to express Dkk1 linked to an IRES GFP (Dkk1-MSCs). Transduced cells were sorted for GFP expression and analyzed by immunoblot for specific protein expression. Dkk-1 levels in conditioned media from transduced cells were $1.29 \pm 0.11 \mu\text{g/ml}$ and undetectable in GFP-MSCs. WT-MSCs transduced with vector containing GFP alone (GFP-MSC) were also sorted in parallel. (b) Cell proliferation assay. (c) β -gluc specific activity normalized to total cellular DNA content of paired GFP-MSC- or Dkk1-MSC-loaded granulation tissue. One way Anova with Bonferroni correction was used to compare data between GFP-MSC and Dkk1-MSC.


a. sFRP2-MSCs are capable of endothelial-lineage differentiation



b. Infarct size



c. MSC engraftment by GFP immunohistochemistry



d. Vascular density of myocardial scar assessed by anti-PECAM-1




Fig. S5. MSC-mediated cardiac therapy. (a) Representative Z plane shows high degree of colocalization of microvascular endothelial cells (anti-PECAM, green) and the sFRP2-MSC marker, GFP (red). Fluorescent images were acquired by confocal fluorescent microscopy with 60x lens. DAPI staining of the same slide shows the location of the nuclei. (b) Representative Masson trichrome-stained sections of hearts from mice 30 days after receiving PBS, GFP-MSC, MRL-MSC or sFRP2-MSC after coronary vessel ligation. MRL and sFRP2-MSC treated hearts had smaller infarcts with less collagen deposition (blue staining in trichrome) and more muscle (increased red staining). (c) Engraftment of sFRP2- and GFP-MSCs was assessed by immunostaining with anti-GFP (brown). sFRP2-MSC showed increased engraftment in both models, however, there was significantly higher engraftment within sponge granulation tissues than in healed myocardial scar. (d) Representative immunostained sections of myocardial scar using anti-PECAM-1 to designate vascular density among experimental cohorts.

Table S1. Wnt pathway inhibitors are up-regulated and Wnt downstream targets are down-regulated in MRL-MSCs

Gene name	Fold Change	<i>P</i>	<i>n</i>
Wnt pathway inhibitors			
Secreted frizzled-related sequence protein 2 (Sfrp2)	251.8 ± 346	<i>P</i> ≤ 0.05	<i>n</i> = 9
Secreted frizzled-related sequence protein 4 (Sfrp4)	31.61 ± 34.97	<i>P</i> ≤ 0.05	<i>n</i> = 6
Dickkopf homolog 1 (Dkk1)	ND	NA	NA
Wnt Downstream Targets			
Axin2	0.1998 ± 0.1364	<i>P</i> < 0.01	<i>n</i> = 7
High mobility group box protein (Sox2)	0.0785 ± 0.0410	<i>P</i> < 0.01	<i>n</i> = 6
Cyclin D1	0.2119 ± 0.1316	<i>P</i> < 0.01	<i>n</i> = 8

Gene expression was analyzed through quantitative real time RT-PCR. Fold changes, *P* values, and number of runs are specified for each gene. ND, not detected; NA, not applicable.

Table S3. Transduction characterizations

Transduct	No. of transductions	Average transduction efficiency, %	Standard deviation, %
GFP	4	50.64	± 24.03
Dkk1	2	85.5	± 14.14
Sfrp2	4	48.12	± 9.61
Wnt3a	6	26.15	± 8.95

Data shows that our experiments were generated from multiple transductions with varying levels of efficiency. The transduction efficiency for sFRP2-MSCs and GFP-MSCs was \approx 50%.

Table S4. Transduction characterizations

Clone	Fold change	<i>P</i>
Control A	1	NA
Control B	1	NA
75B	0.08 ± 0.03	<i>P</i> = 0.048
76B	0.57 ± 0.20	<i>P</i> = 0.117
77C	0.035 ± 0.02	<i>P</i> = 0.059

Real-time RT-PCR analysis of different constructs and control MRL-MSCs. All reactions were carried out in triplicate and the results represent the average ± SD of three independent experiments. Two-tailed paired Student's *t* test was performed.

Table S5. sFRP2-MSCs express several angiogenic factors

Gene ID	Gene Name	Fold Change in sFRP2-MSC
1422516_a.at	Fibp (Fibroblast growth factor intracellular binding protein)	2.2
1433489_s.at	FfgR2 (Fibroblast growth factor receptor 2)	2.1
1419417_at	VegfC (Vascular endothelial growth factor C)	2.3
1418711_at	Pdgfa (Platelet-derived growth factor, alpha)	2.4
1417148_at	Pdgfrb (Platelet derived growth factor receptor, beta polypeptide)	2.6
1421919_a.at	Ccr9 (Chemokine [C-C motif] receptor 9)	11.9
1450652_at	Ctsk (Cathepsin K)	16.7
1450029_s.at	Itga9 (Integrin alpha 9)	2.3
1455158_at	Itga3 (Integrin alpha 3)	2.7
1425039_at	Itgbl1 (Integrin beta-like 1)	5.7
1454966_at	Itga8 (Integrin alpha 8)	4.5
1423268_at	Itga5 (Integrin alpha 5)	3.3
1446180_at	Lamb1-1 (Laminin beta subunit-1)	5.0
1446534_at	Angptl2 (Angiopoietin-like 2)	2.5
1417130_s.at	Angptl4 (Angiopoietin-like 4)	2.2
1419671_a.at	Il17rc (Interleukin 17 receptor C)	2.5
1421670_a.at	Irak4 (Interleukin-1 receptor-associated kinase 4)	2.1
1435040_at	Irak3 (Interleukin-1 receptor-associated kinase 3)	3.6
1448950_at	Il1r1 (Interleukin 1 receptor, type I)	4.4
1443937_at	Il2rb (Interleukin 2 receptor, beta chain)	21.7
1425145_at	Il1r1l (Interleukin 1 receptor-like 1)	3.2
1416295_a.at	Il2rg (Interleukin 2 receptor, gamma chain)	5.2
1425560_a.at	S100a16 (S100 calcium binding protein A16)	2.3
1448367_at	Sdf4 (Stromal derived factor 4)	3.9

Microarray analysis of sFRP2-MSCs revealed up-regulation of several genes associated with angiogenesis in comparison to GFP-MSCs.